阿扎胞苷联合维奈克拉治疗高危骨髓增生异常综合征或慢性粒单核细胞白血病:单中心、剂量递增、剂量扩展1-2期研究的1期结果
这项单中心1-2期研究在23例初治或复发难治高危骨髓增生异常综合征或慢性粒单核细胞白血病患者中评估阿扎胞苷联合维奈克拉的安全性、耐受性和初步活性,未达到最大耐受剂量,推荐2期剂量为阿扎胞苷75 mg/m2用5天联合维奈克拉400 mg用14天,总缓解率87%(95% CI 66-97)。
要点
- 推荐2期剂量为阿扎胞苷75 mg/m2用5天联合维奈克拉400 mg用14天,最大耐受剂量未达到
- 总缓解率87%(95% CI 66-97;23例中20例)
- 最常见3-4级治疗中出现的不良事件为中性粒细胞减少(23例中9例,39%)、血小板减少(9例,39%)、肺部感染(7例,30%)和发热性中性粒细胞减少(4例,17%)
核心结论
- 阿扎胞苷联合维奈克拉在高危骨髓增生异常综合征或慢性粒单核细胞白血病患者中安全并显示出令人鼓舞的活性。
研究设计与样本
- 单中心、剂量递增、剂量扩展1-2期试验,地点为美国德克萨斯州休斯顿的德克萨斯大学MD安德森癌症中心,本文报告1期结果。
- 纳入年龄≥18岁、初治或复发难治高危骨髓增生异常综合征或慢性粒单核细胞白血病且骨髓原始细胞>5%的患者,未采用特定的美国东部肿瘤协作组状态限制。
- 采用3+3设计,主要结局为安全性和耐受性以及确定阿扎胞苷联合维奈克拉的最大耐受剂量和推荐2期剂量,所有接受一剂研究药物的患者均纳入分析。
- 2019年11月12日至2021年12月17日共23例患者入组1期部分,其中17例(74%)为低甲基化药物初治、6例(26%)为低甲基化药物治疗失败后。
- 18例(78%)为男性、5例(22%)为女性;21例(91%)为白人、2例(9%)为亚裔;中位随访13.2个月(IQR 6.8-18.3)。
主要发现
- 最大耐受剂量未达到,推荐2期剂量确定为阿扎胞苷75 mg/m2用5天联合维奈克拉400 mg用14天。
- 最常见3-4级治疗中出现的不良事件为中性粒细胞减少(23例中9例,39%)、血小板减少(9例,39%)、肺部感染(7例,30%)和发热性中性粒细胞减少(4例,17%)。
- 研究药物期间发生3例脓毒症死亡,未认为与治疗相关。
- 总缓解率为87%(95% CI 66-97;23例中20例)。
关键数值与推荐
- 推荐2期剂量为阿扎胞苷75 mg/m2用5天联合维奈克拉400 mg用14天。
- 总缓解率87%(95% CI 66-97;23例中20例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapies beyond hypomethylating agents such as azacitidine are needed in high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents. We therefore aimed to evaluate the safety, tolerability, and preliminary activity of azacitidine combined with venetoclax for treatment-naive and relapsed or refractory high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. METHODS: We did a single centre, dose-escalation, dose-expansion, phase 1-2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). This Article details the phase 1 results. We enrolled patients (≥18 years) with treatment-naive or relapsed or refractory high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia and bone marrow blasts of more than 5%. No specific Eastern Cooperative Oncology Group status restriction was used. Patients were treated with intravenous or subcutaneous azacitidine (75 mg/m2) for 5 days and oral venetoclax (100-400 mg) for 7-14 days. The primary outcome was safety and tolerability as well as determination of the maximum tolerated dose and recommended phase 2 dose of the azacitidine and venetoclax combination using a 3 + 3 study design. All patients who received one dose of study drug were included in the analyses. This study is registered with ClinicalTrials.gov, number NCT04160052. The phase 2 dose-expansion part of the trial is ongoing. FINDINGS: Between Nov 12, 2019, and Dec 17, 2021, a total of 23 patients were enrolled in the phase 1 portion of this study (17 [74%] hypomethylating agent naive and six [26%] post-hypomethylating agent failure). 18 (78%) patients were male and five (22%) were female; 21 (91%) were white and two (9%) were Asian. Median follow-up was 13·2 months (IQR 6·8-18·3). The maximum tolerated dose was not reached and the recommended phase 2 dose was established as azacitidine 75 mg/m2 for 5 days plus venetoclax 400 mg for 14 days. The most common grade 3-4 treatment-emergent adverse events were neutropenia (nine [39%] of 23), thrombocytopenia (nine [39%]), lung infection (seven [30%]), and febrile neutropenia (four [17%]). Three deaths due to sepsis, which were not deemed treatment-related, occurred on the study drugs. The overall response rate was 87% (95% CI 66-97; 20 of 23 patients). INTERPRETATION: Azacitidine with venetoclax is safe and shows encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. FUNDING: MD Anderson Cancer Center.
引用
- Bazinet A, Darbaniyan F, Jabbour E, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022. PMID: 36063832. doi:10.1016/S2352-3026(22)00216-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。